Novel anti-malarial combinations and their toxicity

References

• Krishna S, Woodrow CJ, Staines HM, et al. Re-evaluation of how artemisinins work in light of emerging evidence of in vitro resistance. Trends Mol Med 2006;12(5):200-5
   PubMedGoogle Scholar
• Mercer AE, Maggs JL, Sun XM, et al. Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem 2007;282(13):9372-82
   PubMedGoogle Scholar
• Mercer AE. The role of bioactivation in the pharmacology and toxicology of the artemisinin-based antimalarials. Curr Opin Drug Discov Devel 2009;12(1):125-32
   PubMedGoogle Scholar
• Mercer AE, Copple IM, Maggs JL, et al. The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem 2011;286(2):987-96
   PubMed Web of Science ®Google Scholar
• Arav-Boger R, He R, Chiou CJ, et al. Artemisinin-derived dimers have greatly improved anti-cytomegalovirus activity compared to artemisinin monomers. PLoS One 2010;5(4):e10370
   PubMed Web of Science ®Google Scholar
• D’Angelo JG, Bordon C, Posner GH, et al. Artemisinin derivatives inhibit Toxoplasma gondii in vitro at multiple steps in the lytic cycle. J Antimicrob Chemother 2009;63(1):146-50
   PubMedGoogle Scholar
• Posner GH, McGarvey DJ, Oh CH, et al. Structure-activity relationships of lactone ring-opened analogs of the antimalarial 1,2,4-trioxane artemisinin. J Med Chem 1995;38(4):607-12
   PubMedGoogle Scholar
• Meshnick SR, Taylor TE, Kamchonwongpaisan S. Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol Rev 1996;60(2):301-15
   PubMedGoogle Scholar
• Woodrow CJ, Haynes RK, Krishna S. Artemisinins. Postgrad Med J 2005;81(952):71-8
   PubMed Web of Science ®Google Scholar
• Olliaro PL, Taylor WR. Developing artemisinin based drug combinations for the treatment of drug resistant falciparum malaria: a review. J Postgrad Med 2004;50(1):40-4
   PubMedGoogle Scholar
• Yeung S, Pongtavornpinyo W, Hastings IM, et al. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 2004;71(2 Suppl):179-86
   PubMedGoogle Scholar
• White NJ, Nosten F, Looareesuwan S, et al. Averting a malaria disaster. Lancet 1999;353(9168):1965-7
   PubMed Web of Science ®Google Scholar
• Efferth T, Kaina B. Toxicity of the antimalarial artemisinin and its derivatives. Crit Rev Toxicol 2010;40(5):405-21
   PubMed Web of Science ®Google Scholar
• Brewer TG, Grate SJ, Peggins JO, et al. Fatal neurotoxicity of arteether and artemether. Am J Trop Med Hyg 1994;51(3):251-9
   PubMed Web of Science ®Google Scholar
• Brewer TG, Peggins JO, Grate SJ, et al. Neurotoxicity in animals due to arteether and artemether. Trans R Soc Trop Med Hyg 1994;88 Suppl 1:S33-6
   PubMedGoogle Scholar
• Van Vugt M, Angus BJ, Price RN, et al. A case-control auditory evaluation of patients treated with artemisinin derivatives for multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 2000;62(1):65-9
   PubMedGoogle Scholar
• Hien TT, Turner GD, Mai NT, et al. Neuropathological assessment of artemether-treated severe malaria. Lancet 2003;362(9380):295-6
   PubMed Web of Science ®Google Scholar
• AlKadi HO. Antimalarial drug toxicity: a review. Chemotherapy 2007;53(6):385-91
   PubMed Web of Science ®Google Scholar
• Vugt MV, Wilairatana P, Gemperli B, et al. Efficacy of six doses of artemether-lumefantrine (benflumetol) in multidrug-resistant Plasmodium falciparum malaria. Am J Trop Med Hyg 1999;60(6):936-42
   PubMed Web of Science ®Google Scholar
• Denis MB, Davis TM, Hewitt S, et al. Efficacy and safety of dihydroartemisinin-piperaquine (Artekin) in Cambodian children and adults with uncomplicated falciparum malaria. Clin Infect Dis 2002;35(12):1469-76
   PubMed Web of Science ®Google Scholar
• Jansen FH. The pharmaceutical death-ride of dihydroartemisinin. Malar J 2010;9:212
   PubMedGoogle Scholar
• Stepniewska K, Taylor W, Sirima SB, et al. Population pharmacokinetics of artesunate and amodiaquine in African children. Malar J 2009;8:200
   PubMed Web of Science ®Google Scholar
• Ringwald P, Bickii J, Basco L. Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa. Lancet 1996;347(8993):24-8
   PubMed Web of Science ®Google Scholar
• Looareesuwan S, Kyle DE, Viravan C, et al. Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand. Am J Trop Med Hyg 1996;54(2):205-9
   PubMedGoogle Scholar
• Phompradit P, Muhamad P, Wisedpanichkij R, et al. Four years' monitoring of in vitro sensitivity and candidate molecular markers of resistance of Plasmodium falciparum to artesunate-mefloquine combination in the Thai-Myanmar border. Malar J 2014;13:23
   PubMed Web of Science ®Google Scholar
• Price R, van Vugt M, Phaipun L, et al. Adverse effects in patients with acute falciparum malaria treated with artemisinin derivatives. Am J Trop Med Hyg 1999;60(4):547-55
   PubMed Web of Science ®Google Scholar
• Steketee RW, Wirima JJ, Campbell CC. Developing effective strategies for malaria prevention programs for pregnant African women. Am J Trop Med Hyg 1996;55(1 Suppl):95-100
   PubMedGoogle Scholar
• Steketee RW, Nahlen BL, Parise ME, Menendez C. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg 2001;64(1-2 Suppl):28-35
   PubMedGoogle Scholar
• Li Q, Weina PJ. Severe embryotoxicity of artemisinin derivatives in experimental animals, but possibly safe in pregnant women. Molecules 2010;15(1):40-57
   Google Scholar
• White TE, Bushdid PB, Ritter S, et al. Artesunate-induced depletion of embryonic erythroblasts precedes embryolethality and teratogenicity in vivo. Birth Defects Res B Dev Reprod Toxicol 2006;77(5):413-29
   PubMedGoogle Scholar
• Amorim MH, Gil da Costa RM, Lopes C, Bastos MM. Sesquiterpene lactones: adverse health effects and toxicity mechanisms. Crit Rev Toxicol 2013;43(7):559-79
   PubMed Web of Science ®Google Scholar
• Abolaji AO, Eteng MU, Ebong PE, et al. A safety assessment of the antimalarial herb Artemisia annua during pregnancy in Wistar rats. Phytother Res 2013;27(5):647-54
   PubMedGoogle Scholar
• Longo M, Zanoncelli S, Brughera M, et al. Comparative embryotoxicity of different antimalarial peroxides: in vitro study using the rat whole embryo culture model (WEC). Reprod Toxicol 2010;30(4):583-90
   PubMedGoogle Scholar
• Longo M, Zanoncelli S, Della Torre P, et al. Investigations of the effects of the antimalarial drug dihydroartemisinin (DHA) using the Frog Embryo Teratogenesis Assay-Xenopus (FETAX). Reprod Toxicol 2008;25(4):433-41
   PubMedGoogle Scholar
• D’Alessandro S, Gelati M, Basilico N, et al. Differential effects on angiogenesis of two antimalarial compounds, dihydroartemisinin and artemisone: implications for embryotoxicity. Toxicology 2007;241(1-2):66-74
   PubMed Web of Science ®Google Scholar
• Copple IM, Mercer AE, Firman J, et al. Examination of the cytotoxic and embryotoxic potential and underlying mechanisms of next-generation synthetic trioxolane and tetraoxane antimalarials. Mol Med 2012;18:1045-55
   PubMed Web of Science ®Google Scholar
• Clark RL. Effects of artemisinins on reticulocyte count and relationship to possible embryotoxicity in confirmed and unconfirmed malarial patients. Birth Defects Res A Clin Mol Teratol 2012;94(2):61-75
   PubMedGoogle Scholar
• Clark RL, Brannen KC, Sanders JE, Hoberman AM. Artesunate and artelinic acid: association of embryotoxicity, reticulocytopenia, and delayed stimulation of hematopoiesis in pregnant rats. Birth Defects Res B Dev Reprod Toxicol 2011;92(1):52-68
   PubMedGoogle Scholar
• Rijken MJ, McGready R, Boel ME, et al. Dihydroartemisinin-piperaquine rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Am J Trop Med Hyg 2008;78(4):543-5
   PubMed Web of Science ®Google Scholar
• Mutabingwa TK, Muze K, Ord R, et al. Randomized trial of artesunate+amodiaquine, sulfadoxine-pyrimethamine+amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania. PLoS One 2009;4(4):e5138
   PubMed Web of Science ®Google Scholar
• Du JH, Zhang HD, Ma ZJ, Ji KM. Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol 2010;65(5):895-902
   PubMedGoogle Scholar
• Zhao F, Wang H, Kunda P, et al. Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71. Oncol Rep 2013;30(3):1473-82
   PubMedGoogle Scholar
• Wang S, Sasaki T. Synthesis of artemisinin dimers using the Ugi reaction and their in vitro efficacy on breast cancer cells. Bioorg Med Chem Lett 2013;23(15):4424-7
   PubMedGoogle Scholar
• Tan SS, Ong B, Cheng C, et al. Anti-malarial drug artesunate inhibits primary human cultured airway smooth muscle cell proliferation. Am J Respir Cell Mol Biol 2014;50(2):451-8
   PubMedGoogle Scholar
• Finaurini S, Basilico N, Corbett Y, et al. Dihydroartemisinin inhibits the human erythroid cell differentiation by altering the cell cycle. Toxicology 2012;300(1-2):57-66
   PubMed Web of Science ®Google Scholar
• Totino PR, Daniel-Ribeiro CT, Ferreira-da-Cruz Mde F. Pro-apoptotic effects of antimalarial drugs do not affect mature human erythrocytes. Acta Trop 2009;112(2):236-8
   PubMedGoogle Scholar
• Aquino I, Perazzo FF, Maistro EL. Genotoxicity assessment of the antimalarial compound artesunate in somatic cells of mice. Food Chem Toxicol 2011;49(6):1335-9
   PubMed Web of Science ®Google Scholar
• Mota TC, Cardoso PC, Gomes LM, et al. In vitro evaluation of the genotoxic and cytotoxic effects of artesunate, an antimalarial drug, in human lymphocytes. Environ Mol Mutagen 2011;52(7):590-4
   PubMed Web of Science ®Google Scholar
• Li T, Chen H, Yang Z, et al. Evaluation of the immunosuppressive activity of artesunate in vitro and in vivo. Int Immunopharmacol 2013;16(2):306-12
   PubMedGoogle Scholar
• Li T, Chen H, Wei N, et al. Anti-inflammatory and immunomodulatory mechanisms of artemisinin on contact hypersensitivity. Int Immunopharmacol 2012;12(1):144-50
   PubMed Web of Science ®Google Scholar
• Kreeftmeijer-Vegter AR, van Genderen PJ, Visser LG, et al. Treatment outcome of intravenous artesunate in patients with severe malaria in the Netherlands and Belgium. Malar J 2012;11:102
   PubMedGoogle Scholar
• Zoller T, Junghanss T, Kapaun A, et al. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 2011;17(5):771-7
   PubMedGoogle Scholar
• Jarvis JN, Coltart CE, Pule M, et al. Artemisinin therapy and severe delayed haemolysis. Lancet 2013;382(9887):180
   PubMedGoogle Scholar
• Caramello P, Balbiano R, De Blasi T, et al. Severe malaria, artesunate and haemolysis. J Antimicrob Chemother 2012;67(8):2053-4
   PubMedGoogle Scholar
• Rolling T, Schmiedel S, Wichmann D, et al. Post-treatment haemolysis in severe imported malaria after intravenous artesunate: case report of three patients with hyperparasitaemia. Malar J 2012;11:169
   PubMedGoogle Scholar
• Thanh NX, Trung TN, Phong NC, et al. The efficacy and tolerability of artemisinin-piperaquine (Artequick(R)) versus artesunate-amodiaquine (Coarsucam) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam. Malar J 2012;11:217
   PubMedGoogle Scholar
• Bhatt KM, Samia BM, Bhatt SM, Wasunna KM. Efficacy and safety of an artesunate/mefloquine combination, (artequin) in the treatment of uncomplicated P. falciparum malaria in Kenya. East Afr Med J 2006;83(5):236-42
   PubMedGoogle Scholar
• Gargano N, Ubben D, Tommasini S, et al. Therapeutic efficacy and safety of dihydroartemisinin-piperaquine versus artesunate-mefloquine in uncomplicated Plasmodium falciparum malaria in India. Malar J 2012;11:233
   PubMed Web of Science ®Google Scholar
• Djalle D, Njuimo SP, Manirakiza A, et al. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J 2014;13(1):9
   PubMedGoogle Scholar
• Zwang J, Ndiaye JL, Djimde A, et al. Comparing changes in haematologic parameters occurring in patients included in randomized controlled trials of artesunate-amodiaquine vs single and combination treatments of uncomplicated falciparum in sub-Saharan Africa. Malar J 2012;11:25
   PubMedGoogle Scholar
• Croft SL, Duparc S, Arbe-Barnes SJ, et al. Review of pyronaridine anti-malarial properties and product characteristics. Malar J 2012;11:270
   PubMed Web of Science ®Google Scholar
• Raghavamenon AC, Muyiwa AF, Davis LK, Uppu RM. Dihydroartemisinin induces caspase-8-dependent apoptosis in murine GT1-7 hypothalamic neurons. Toxicol Mech Methods 2011;21(5):367-73
   PubMed Web of Science ®Google Scholar
• Wesche DL, DeCoster MA, Tortella FC, Brewer TG. Neurotoxicity of artemisinin analogs in vitro. Antimicrob Agents Chemother 1994;38(8):1813-19
   PubMedGoogle Scholar
• Brewer TG, Genovese RF, Newman DB, Li Q. Factors relating to neurotoxicity of artemisinin antimalarial drugs "listening to arteether". Med Trop (Mars) 1998;58(3 Suppl):22-7
   PubMedGoogle Scholar
• Li QG, Peggins JO, Lin AJ, et al. Pharmacology and toxicology of artelinic acid: preclinical investigations on pharmacokinetics, metabolism, protein and red blood cell binding, and acute and anorectic toxicities. Trans R Soc Trop Med Hyg 1998;92(3):332-40
   PubMed Web of Science ®Google Scholar
• Genovese RF, Newman DB, Petras JM, Brewer TG. Behavioral and neural toxicity of arteether in rats. Pharmacol Biochem Behav 1998;60(2):449-58
   PubMedGoogle Scholar
• Genovese RF, Newman DB, Li Q, et al. Dose-dependent brainstem neuropathology following repeated arteether administration in rats. Brain Res Bull 1998;45(2):199-202
   PubMedGoogle Scholar
• Li QG, Brueckner RP, Peggins JO, et al. Arteether toxicokinetics and pharmacokinetics in rats after 25 mg/kg/day single and multiple doses. Eur J Drug Metab Pharmacokinet 1999;24(3):213-23
   PubMedGoogle Scholar
• Genovese RF, Newman DB, Gordon KA, Brewer TG. Acute high dose arteether toxicity in rats. Neurotoxicology 1999;20(5):851-9
   PubMedGoogle Scholar
• Genovese RF, Newman DB, Brewer TG. Behavioral and neural toxicity of the artemisinin antimalarial, arteether, but not artesunate and artelinate, in rats. Pharmacol Biochem Behav 2000;67(1):37-44
   PubMedGoogle Scholar
• Li Q, Hickman M. Toxicokinetic and toxicodynamic (TK/TD) evaluation to determine and predict the neurotoxicity of artemisinins. Toxicology 2011;279(1-3):1-9
   PubMed Web of Science ®Google Scholar
• Beckman DA, Youreneff M, Butt MT. Neurotoxicity assessment of artemether in juvenile rats. Birth Defects Res B Dev Reprod Toxicol 2013;98(2):183-99
   PubMedGoogle Scholar
• Eigbibhalu UG, Albert Taiwo EO, Douglass IA, Abimbola EA. Effect of selected anti-malarial drugs on the blood chemistry and brain serotonin levels in male rabbits. Pak J Pharm Sci 2013;26(1):125-9
   PubMedGoogle Scholar
• Das D, Tripura R, Phyo AP, et al. Effect of high-dose or split-dose artesunate on parasite clearance in artemisinin-resistant falciparum malaria. Clin Infect Dis 2013;56(5):e48-58
   PubMedGoogle Scholar
• White NJ. Cardiotoxicity of antimalarial drugs. Lancet Infect Dis 2007;7(8):549-58
   PubMed Web of Science ®Google Scholar
• Bukauskas FF, Kreuzberg MM, Rackauskas M, et al. Properties of mouse connexin 30.2 and human connexin 31.9 hemichannels: implications for atrioventricular conduction in the heart. Proc Natl Acad Sci USA 2006;103(25):9726-31
   PubMedGoogle Scholar
• Coker SJ, Batey AJ, Lightbown ID, et al. Effects of mefloquine on cardiac contractility and electrical activity in vivo, in isolated cardiac preparations, and in single ventricular myocytes. Br J Pharmacol 2000;129(2):323-30
   PubMed Web of Science ®Google Scholar
• Maude RJ, Plewes K, Faiz MA, et al. Does artesunate prolong the electrocardiograph QT interval in patients with severe malaria? Am J Trop Med Hyg 2009;80(1):126-32
   PubMedGoogle Scholar
• Adjei GO, Oduro-Boatey C, Rodrigues OP, et al. Electrocardiographic study in Ghanaian children with uncomplicated malaria, treated with artesunate-amodiaquine or artemether-lumefantrine. Malar J 2012;11:420
   PubMedGoogle Scholar
• Ngouesse B, Basco LK, Ringwald P, et al. Cardiac effects of amodiaquine and sulfadoxine-pyrimethamine in malaria-infected African patients. Am J Trop Med Hyg 2001;65(6):711-16
   PubMedGoogle Scholar
• Owumi SE, Gbadegesin MA, Odunola OA, et al. Toxicity associated with repeated administration of artemether-lumefantrine in rats. Environ Toxicol 2013. [Epub ahead of print]
   PubMedGoogle Scholar
• Kurth F, Belard S, Basra A, Ramharter M. Pyronaridine-artesunate combination therapy for the treatment of malaria. Curr Opin Infect Dis 2011;24(6):564-9
   PubMedGoogle Scholar
• Larrey D, Castot A, Pessayre D, et al. Amodiaquine-induced hepatitis. A report of seven cases. Ann Intern Med 1986;104(6):801-3
   PubMed Web of Science ®Google Scholar
• Mishra SK, Singh P, Rath SK. A study of toxicity and differential gene expression in murine liver following exposure to anti-malarial drugs: amodiaquine and sulphadoxine-pyrimethamine. Malar J 2011;10:109
   PubMedGoogle Scholar
• Li Q, Xie LH, Johnson TO, et al. Toxicity evaluation of artesunate and artelinate in Plasmodium berghei-infected and uninfected rats. Trans R Soc Trop Med Hyg 2007;101(2):104-12
   PubMed Web of Science ®Google Scholar
• Leonardi E, Gilvary G, White NJ, Nosten F. Severe allergic reactions to oral artesunate: a report of two cases. Trans R Soc Trop Med Hyg 2001;95(2):182-3
   PubMed Web of Science ®Google Scholar
• Brasseur P, Vaillant MT, Olliaro PL. Anti-malarial drug safety information obtained through routine monitoring in a rural district of South-Western Senegal. Malar J 2012;11:402
   PubMedGoogle Scholar
• Zwang J, Dorsey G, Djimde A, et al. Clinical tolerability of artesunate-amodiaquine versus comparator treatments for uncomplicated falciparum malaria: an individual-patient analysis of eight randomized controlled trials in sub-Saharan Africa. Malar J 2012;11:260
   PubMedGoogle Scholar
• Sirima SB, Tiono AB, Gansane A, et al. The efficacy and safety of a new fixed-dose combination of amodiaquine and artesunate in young African children with acute uncomplicated Plasmodium falciparum. Malar J 2009;8:48
   PubMedGoogle Scholar
• Thiam S, Ndiaye JL, Diallo I, et al. Safety monitoring of artemisinin combination therapy through a national pharmacovigilance system in an endemic malaria setting. Malar J 2013;12:54
   PubMedGoogle Scholar
• Toure OA, Penali LK, Yapi JD, et al. A comparative, randomized clinical trial of artemisinin/naphtoquine twice daily one day versus artemether/lumefantrine six doses regimen in children and adults with uncomplicated falciparum malaria in Cote d’Ivoire. Malar J 2009;8:148
   PubMedGoogle Scholar
• Zoungrana A, Coulibaly B, Sie A, et al. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PLoS One 2008;3(2):e1630
   PubMed Web of Science ®Google Scholar
• Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012;12(11):851-8
   PubMed Web of Science ®Google Scholar
• Nwakanma DC, Duffy CW, Amambua-Ngwa A, et al. Changes in malaria parasite drug resistance in an endemic population over a 25-year period with resulting genomic evidence of selection. J Infect Dis 2014;209(7):1126-35
   PubMedGoogle Scholar
• Fairhurst RM, Nayyar GM, Breman JG, et al. Artemisinin-resistant malaria: research challenges, opportunities, and public health implications. Am J Trop Med Hyg 2012;87(2):231-41
   PubMed Web of Science ®Google Scholar
• Valecha N, Looareesuwan S, Martensson A, et al. Arterolane, a new synthetic trioxolane for treatment of uncomplicated Plasmodium falciparum malaria: a phase II, multicenter, randomized, dose-finding clinical trial. Clin Infect Dis 2010;51(6):684-91
   PubMed Web of Science ®Google Scholar
• Gupta A, Singh Y, Srinivas KS, et al. Development and validation of a headspace gas chromatographic method for the determination of residual solvents in arterolane (RBx11160) maleate bulk drug. J Pharm Bioallied Sci 2010;2(1):32-7
   PubMedGoogle Scholar
• Fugi MA, Wittlin S, Dong Y, Vennerstrom JL. Probing the antimalarial mechanism of artemisinin and OZ277 (arterolane) with nonperoxidic isosteres and nitroxyl radicals. Antimicrob Agents Chemother 2010;54(3):1042-6
   PubMedGoogle Scholar
• Dong Y, Wittlin S, Sriraghavan K, et al. The structure-activity relationship of the antimalarial ozonide arterolane (OZ277). J Med Chem 2010;53(1):481-91
   PubMed Web of Science ®Google Scholar
• Gautam A, Ahmed T, Sharma P, et al. Pharmacokinetics and pharmacodynamics of arterolane maleate following multiple oral doses in adult patients with P. falciparum malaria. J Clin Pharmacol 2011;51(11):1519-28
   PubMed Web of Science ®Google Scholar
• Valecha N, Krudsood S, Tangpukdee N, et al. Arterolane maleate plus piperaquine phosphate for treatment of uncomplicated Plasmodium falciparum malaria: a comparative, multicenter, randomized clinical trial. Clin Infect Dis 2012;55(5):663-71
   PubMed Web of Science ®Google Scholar
• Saha N, Moehrle JJ, Zutshi A, et al. Safety, tolerability and pharmacokinetic profile of single and multiple oral doses of arterolane (RBx11160) maleate in healthy subjects. J Clin Pharmacol 2014;54(4):386-93
   PubMedGoogle Scholar
• Si Y, Li Q, Xie L, et al. Neurotoxicity and toxicokinetics of artelinic acid following repeated oral administration in rats. Int J Toxicol 2007;26(5):401-10
   PubMed Web of Science ®Google Scholar
• Ansari MT, Saify ZS, Sultana N, et al. Malaria and artemisinin derivatives: an updated review. Mini Rev Med Chem 2013;13(13):1879-902
   PubMed Web of Science ®Google Scholar
• Nagelschmitz J, Voith B, Wensing G, et al. First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone. Antimicrob Agents Chemother 2008;52(9):3085-91
   PubMed Web of Science ®Google Scholar
• Obaldia N 3rd, Kotecka BM, Edstein MD, et al. Evaluation of artemisone combinations in Aotus monkeys infected with Plasmodium falciparum. Antimicrob Agents Chemother 2009;53(8):3592-4
   PubMed Web of Science ®Google Scholar
• Crandall IE, Wasilewski E, Bello AM, et al. Antimalarial activities of 6-iodouridine and its prodrugs and potential for combination therapy. J Med Chem 2013;56(6):2348-58
   PubMedGoogle Scholar
• Barends M, Jaidee A, Khaohirun N, et al. In vitro activity of ferroquine (SSR 97193) against Plasmodium falciparum isolates from the Thai-Burmese border. Malar J 2007;6:81
   PubMedGoogle Scholar
• Staehli Hodel EM, Guidi M, Zanolari B, et al. Population pharmacokinetics of mefloquine, piperaquine and artemether-lumefantrine in Cambodian and Tanzanian malaria patients. Malar J 2013;12:235
   PubMed Web of Science ®Google Scholar
• Pawluk SA, Wilby KJ, Ensom MH. Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children. Clin Pharmacokinet 2013;52(3):153-67
   PubMedGoogle Scholar
• Tarning J, Zongo I, Some FA, et al. Population pharmacokinetics and pharmacodynamics of piperaquine in children with uncomplicated falciparum malaria. Clin Pharmacol Ther 2012;91(3):497-505
   PubMed Web of Science ®Google Scholar
• Salman S, Page-Sharp M, Batty KT, et al. Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria. Antimicrob Agents Chemother 2012;56(6):3288-97
   PubMed Web of Science ®Google Scholar
• Mercer AE, Sarr Sallah M. The pharmacokinetic evaluation of artemisinin drugs for the treatment of malaria in paediatric populations. Expert Opin Drug Metab Toxicol 2011;7(4):427-39
   PubMed Web of Science ®Google Scholar
• Mutabingwa TK, Adam I. Use of artemether-lumefantrine to treat malaria during pregnancy: what do we know and need to know? Expert Rev Anti Infect Ther 2013;11(2):125-35
   PubMed Web of Science ®Google Scholar
• Manyando C, Kayentao K, D’Alessandro U, et al. A systematic review of the safety and efficacy of artemether-lumefantrine against uncomplicated Plasmodium falciparum malaria during pregnancy. Malar J 2012;11:141
   PubMedGoogle Scholar
• Hoglund RM, Adam I, Hanpithakpong W, et al. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan. Malar J 2012;11:398
   PubMed Web of Science ®Google Scholar
• McGready R, Phyo AP, Rijken MJ, et al. Artesunate/dihydroartemisinin pharmacokinetics in acute falciparum malaria in pregnancy: absorption, bioavailability, disposition and disease effects. Br J Clin Pharmacol 2012;73(3):467-77
   PubMed Web of Science ®Google Scholar
• Wilby KJ, Ensom MH. Pharmacokinetics of antimalarials in pregnancy: a systematic review. Clin Pharmacokinet 2011;50(11):705-23
   PubMedGoogle Scholar
• White NJ, Pongtavornpinyo W, Maude RJ, et al. Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 2009;8:253
   PubMed Web of Science ®Google Scholar
• Kurth F, Belard S, Adegnika AA, et al. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infect Dis 2010;10(2):125-32
   PubMed Web of Science ®Google Scholar
• Wang TY. Follow-up observation on the therapeutic effects and remote reactions of artemisinin (Qinghaosu) and artemether in treating malaria in pregnant woman. J Tradit Chin Med 1989;9(1):28-30
   PubMedGoogle Scholar
• Guo XBF, Fu LC, Fan TT, et al. Clinical trials on qinghaosu and its derivatives. Guangzhou College of Traditional Chinese Medicine 1999;39-42,59–63.
   Google Scholar
• Li GQ, Guo XB, Fu LC, et al. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg 1994;88(Suppl 1):S5-6
   PubMed Web of Science ®Google Scholar
• Sowunmi A, Oduola AM, Ogundahunsi OA, et al. Randomised trial of artemether versus artemether and mefloquine for the treatment of chloroquine/sufadoxine-pyrimethamine-resistant falciparum malaria during pregnancy. J Obstet Gynaecol 1998;18(4):322-7
   PubMedGoogle Scholar
• McGready R, Cho T, Cho JJ, et al. Artemisinin derivatives in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 1998;92(4):430-3
   PubMedGoogle Scholar
• McGready R, Cho T, Samuel et al. Randomized comparison of quinine-clindamycin versus artesunate in the treatment of falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2001;95(6):651-6
   PubMed Web of Science ®Google Scholar
• Adam I, Elwasila E, Mohammed Ali DA, et al. Artemether in the treatment of falciparum malaria during pregnancy in eastern Sudan. Trans R Soc Trop Med Hyg 2004;98(9):509-13
   PubMed Web of Science ®Google Scholar
• McGready R, Tan SO, Ashley EA, et al. A randomised controlled trial of artemether-lumefantrine versus artesunate for uncomplicated plasmodium falciparum treatment in pregnancy. PLoS Med 2008;5(12):e253
   PubMed Web of Science ®Google Scholar
• Adam I, Elhassan EM, Omer EM, et al. Safety of artemisinins during early pregnancy, assessed in 62 Sudanese women. Ann Trop Med Parasitol 2009;103(3):205-10
   PubMed Web of Science ®Google Scholar
• McGready R, Brockman A, Cho T, et al. Randomized comparison of mefloquine-artesunate versus quinine in the treatment of multidrug-resistant falciparum malaria in pregnancy. Trans R Soc Trop Med Hyg 2000;94(6):689-93
   PubMed Web of Science ®Google Scholar
• Bounyasong S. Randomized trial of artesunate and mefloquine in comparison with quinine sulfate to treat P. falciparum malaria pregnant women. J Med Assoc Thai 2001;84:1289-99
   PubMedGoogle Scholar
• Deen JL, von Seidlein L, Pinder M, et al. The safety of the combination artesunate and pyrimethamine-sulfadoxine given during pregnancy. Trans R Soc Trop Med Hyg 2001;95(4):424-8
   PubMed Web of Science ®Google Scholar
• McGready R, Keo NK, Villegas L, et al. Artesunate-atovaquone-proguanil rescue treatment of multidrug-resistant Plasmodium falciparum malaria in pregnancy: a preliminary report. Trans R Soc Trop Med Hyg 2003;97(5):592-4
   PubMed Web of Science ®Google Scholar
• McGready R, Ashley EA, Moo E, et al. A randomized comparison of artesunate-atovaquone-proguanil versus quinine in treatment for uncomplicated falciparum malaria during pregnancy. J Infect Dis 2005;192(5):846-53
   PubMed Web of Science ®Google Scholar
• Adam I, Ali DM, Abdalla MA. Artesunate plus sulfadoxine-pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria during pregnancy in eastern Sudan. Trans R Soc Trop Med Hyg 2006;100(7):632-5
   PubMedGoogle Scholar
• Kalilani L, Mofolo I, Chaponda M, et al. A randomized controlled pilot trial of azithromycin or artesunate added to sulfadoxine-pyrimethamine as treatment for malaria in pregnant women. PLoS One 2007;2(11):e1166
   PubMedGoogle Scholar
• Kaye DK, Nshemerirwe R, Mutyaba TS, Ndeezi G. A randomized clinical trial comparing safety, clinical and parasitological response to artemether-lumefantrine and chlorproguanil-dapsone i treatment of uncomplicated malaria in pregnancy in Mulago hospital, Uganda. J Infect Dev Ctries 2008;2(2):135-9
   PubMed Web of Science ®Google Scholar